Novartis’ Pluvicto Gains Expanded FDA Approval for Prostate Cancer Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received expanded indication approval from...
Novartis
Novartis’ Fabhalta Approved by FDA for C3 Glomerulopathy Treatment
Swiss pharmaceutical giant Novartis’ (NYSE: NVS) iptacopan, marketed as Fabhalta, has received approval from the...
Novartis’ Cosentyx Approved by NMPA for Moderate to Severe Hidradenitis Suppurativa
Swiss giant Novartis’ (NYSE: NVS) Cosentyx (secukinumab) has secured another indication approval from China’s National...
Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results
China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting...
Kyorin Pharmaceutical Licenses KRP-M223 to Novartis for Global Development
Japan-based Kyorin Pharmaceutical Co., Ltd. announced a licensing agreement with Novartis (NYSE: NVS), granting the...
Hengrui’s Vunakizumab Receives NMPA Approval for nr-axSpA Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received another clinical trial...
Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio
Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...
CSPC Pharmaceutical’s Omalizumab Biosimilar Wins NMPA Approval for Allergic Asthma
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received an additional indication approval from the...
Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306...
Novartis Reports 12% YOY Growth in Full-Year Net Sales
Swiss pharmaceutical major Novartis (NYSE: NVS) has released its Q4 and full-year 2024 financial report,...
Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA
China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...
Novartis to Defend Entresto Patent After CAFC Ruling
Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for...
Light Horse Therapeutics Partners with Novartis in First-in-Class Drug Development
US-based Light Horse Therapeutics Inc., a small molecule drug developer that recently emerged from the...
Novartis Announces Positive Results from Phase III STEER Study on SMA Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive topline results from the Phase III...
BioAge Labs and Novartis Partner to Discover Aging-Related Therapeutic Targets
US-based BioAge Labs, Inc. has announced a strategic research partnership with Swiss pharmaceutical giant Novartis...
UCB’s Minzasolmin Fails to Meet Endpoints in ORCHESTRA Study for Early Parkinson’s
Belgium-based biopharmaceutical company UCB (EBR: UCB) has announced the disappointing results of the ORCHESTRA proof-of-concept...
Xtalpi Inc. Partners with Gnosis Neurodynamics to Develop Neural Drug Screening Platform
Shenzhen-based QuantumPharm Inc., trading as Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with...
Siemens Healthineers AG Acquires Advanced Accelerator Applications to Boost PETNET Solutions
Germany-based Siemens Healthineers AG (ETR: SHL) has announced the completion of its acquisition of Advanced...
Novartis’ Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024
Swiss pharmaceutical giant Novartis (NYSE: NVS) presented updated results from the pivotal Phase III NATALEE...
Lee’s Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...